Hanmi Pharmaceutical Company Limited

This study looks at how well a single tablet combining three blood pressure medicines—amlodipine, losartan, and chlorthalidone—works in Korean adults with hypertension. Researchers will track changes in blood pressure over six months and note any side effects. The goal is to see …

This study tests a new medicine called HM15275 in people with type 2 diabetes. The goal is to see if it can lower blood sugar levels (HbA1c) safely over 36 weeks. About 180 adults who manage their diabetes with diet, exercise, or metformin will take part. Half will get the drug, …

This phase 2 trial tests a new drug called HM15912 (sonefpeglutide) in 18 adults with short bowel syndrome who need intravenous nutrition. The study aims to see if the drug is safe and can help the gut absorb more nutrients, potentially reducing the need for IV support. Participa…

This early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…

This Phase 3 trial tests an experimental drug called HM11260C in adults with type 2 diabetes whose blood sugar is not well controlled with metformin and dapagliflozin. About 118 participants will receive either HM11260C or a placebo, and researchers will measure changes in HbA1c …

This early-stage trial is testing a new drug, HM17321, to see if it is safe and how the body processes it. About 90 healthy and obese adults will receive either the drug or a placebo as a shot under the skin. The main goal is to check for side effects, not to treat obesity yet.

This phase 2 trial is testing two oral drugs, belvarafenib and cobimetinib, in about 45 people with advanced or spreading melanoma that has a specific genetic change called an NRAS mutation. The goal is to see if the combination can shrink tumors and keep the disease under contro…

This early-phase trial is testing an experimental drug called HM16390, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and che…